We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MindMed, a biotech company developing psychedelic-inspired therapies, announced the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years conducting clinical research on pain.